B School for Public Policy
A Puzzle with a Missing Piece: Evaluating the Pricing of New Patented Drugs
Seminar by Professor Mark Pauly
Pharmaceutical companies started 2019 by raising the list prices on hundreds of drugs, sparking a new round of controversy around the high costs faced by consumers. The cost issue is particularly pronounced for drugs that are patented and for which there are no available generics or biosimilars. In this seminar, the renowned health care economist Mark Pauly will examine the different factors at play in determining the pricing of new, patented drugs.